Respiratory syncytial virus is a common virus which frequently causes severe lower tract disease in immunocompromised patients. The mortality rate in bone marrow transplant patients with lower tract disease varies from 31% to 100%, depending upon the treatment used, time before initiation of treatment, and whether patients are pre-or post-engraftment. Therapy with inhaled ribavirin has been used with limited success in decreasing mortality rate. Because of concern about conversion from upper respiratory tract disease to lower respiratory tract disease, we conducted a pilot study using aerosolized ribavirin in asymptomatic RSV-positive patients. Patients had NP washes performed on a weekly basis during the RSV season, for the presence of RSV. If patients were positive, but asymptomatic, and could have their transplant postponed, they were treated with ribavirin until negative. Patients who could not be postponed received aerosolized ribavirin, and began transplant conditioning. During this study, we performed 145 nasal aspirations for RSV on 25 patients; 10 aspirates were positive in seven asymptomatic patients. All positive events were successfully treated with ribavirin, which cleared the RSV for a minimum of 3 weeks. No patients became symptomatic. Thus, we conclude that ribavirin can clear asymptomatic infections in immunocompromised pediatric transplant patients.
31% to 100% depending on the treatment used, time before initiation of treatment, and whether patients are pre-or post-engraftment at the time of developing lower tract disease. [1] [2] [3] [4] Therapy with inhaled ribavirin, with or without intravenous immunoglobulin, has been used for patients with upper tract disease, with apparent success in decreasing the incidence of progression to pneumonia, and a decrease in the mortality rate in those patients who did develop pneumonia. [5] [6] [7] The asymptomatic infection rate in the general population during RSV season (usually November to April) appears substantial, but the exact percentage is unknown. Therefore, the progression rate from an asymptomatic infection to a symptomatic disease state with either upper or lower respiratory tract disease is unknown, both in the immunologically normal host and in the marrow transplant population. We screened all patients during the RSV season both at the time of admission, and weekly during transplant, and found an 8% asymptomatic infection rate in our transplant population, plus a 40% asymptomatic infection rate in staff members caring for transplant patients during the 1995-1996 season (unpublished data). Because of the high rate of progression from upper respiratory tract disease to lower respiratory tract involvement in the transplant population (50%), and the high mortality rate once lower respiratory tract disease has developed, we conducted a pilot study of the use of aerosolized ribavirin for asymptomatic, RSV-positive patients within the pediatric bone marrow transplant unit at Primary Children's Medical Center (PCMC), a pediatric tertiary care facility affiliated with the University of Utah School of Medicine and Utah Blood and Marrow Transplant Program.
Methods
All patients considered for admission for stem cell transplantation during the RSV season at PCMC underwent a nasopharyngeal (NP) wash 2-3 days prior to admission. Specimens were tested by direct florescent antibody (DFA) and ELISA. If a child tested positive for RSV by either DFA or ELISA, and the transplant could safely be postponed, admission for transplant was delayed until the patient became RSV-negative. If the transplant could not be postponed, and the patient was asymptomatic, the child was admitted into the Transplant Unit, and received 5 days of high-dose, short duration, 8, 9 aerosolized ribavirin, 2 g in 33 ml sterile water (60 mg/ml), three times a day for 5 days. Ribavirin was then discontinued and the patient underwent repeat NP testing 48 and 72 h after completing ribavirin. A child was considered RSV negative if two negative NP washings had been documented separated by 24 h. Patients who remained RSV-positive at 48 or 72 h after 5 days of ribavirin received a second 5-day course of ribavirin, plus the addition of respiratory syncytial virus-immune globulin (RSVIG). Once patients were admitted to the transplant unit, they underwent weekly NP washes to screen for RSV.
Any patient who developed a positive RSV NP wash was treated in the manner described above. Nasopharyngeal specimens obtained through NP aspiration were sent to the clinical microbiology laboratory for RSV antigen testing. Enzyme-linked fluorescent immunoassay (ELISA; VIDAS, Vitek Immuno-diagnostic Assay System, Biomerieux Vitek, Hazelwood, MO, USA) was the procedure used in our laboratory. A positive test by ELISA was considered positive, and the patient was treated with ribavirin. Specimens that tested negative by ELISA were re-tested by direct fluorescent antibody (DFA; Bartils Respiratory Syncytial Virus direct fluorescent antibody kit, Bartils, Issaquah, WA, USA) to confirm the negative test.
Specimens contaminated by blood were tested using DFA. While specific performance data are not available for our laboratory, the following published data are available. The sensitivity and specificity for ELISA are 81.7% and 93.6%, and DFA are 91.9% and 96.4%. 10 Those patients who required the addition of RSV-IG received Respiratory Syncytial Virus Immune Globulin (RSV-IG; Respigam, Massachusetts Public Health Biologic Laboratories and Medimmune, Inc, Gaithersburg, MD, USA), a commercially available product. This was obtained from the hospital pharmacy and administered intravenously according to the recommended guidelines.
11,12
Nasopharyngeal wash technique NP washes were performed weekly by BMT nurses specifically trained in the procedure. Samples were obtained using a vacuum-assisted small suction catheter inserted into the nose and directed toward the nasopharynx. The specimen was considered adequate only if there were epithelial cells present on DFA/ELISA examination. Inadequate samples were re-obtained.
Patient selection
All patients admitted to the University of Utah Pediatric Bone Marrow Transplant Unit at Primary Children's Medical Center in Salt Lake City during the RSV season were eligible. Table 1 shows patient characteristics of all patients tested. Patients were excluded from this protocol if they had symptoms of either upper or lower respiratory tract disease, including rhinorrhea, sinus congestion, pharyngitis, otitis, cough, or abnormal chest radiograph. On admission, patients were placed in a HEPA-filtered room. All individuals entering any patient room were required to wash their hands and wear a gown, mask and gloves prior to entering. 
Results
From January to December 1996, 38 screening NP washes were performed on 14 patients ( Table 2 ). All these patients had received their transplant preparative regimen prior to testing, and were between 1 day and 6 months post-transplant. Three patients were RSV positive but asymptomatic and received the ribavirin treatment as described previously. All patients became RSV-negative with this therapy. During the 1997 calendar year, 107 tests were performed on 13 different patients. Two patients were admitted in the fall of 1996, and therefore were initially tested and reported in the 1996 data. Patients were tested 1-2 days prior to admission, then weekly throughout the RSV season or until off all immunosuppression. Two patients (UUPN Nos 356 and 357) tested positive at the time of their admission for transplant, were asymptomatic, and proceeded with the preparative regimen while receiving ribavirin. Table 3 summarizes the clinical data of all patients testing positive for RSV. Eight of 13 patients remained negative throughout the transplant course. Three patients converted to positive status once, and all three patients cleared the RSV after 5 days of ribavirin therapy. Two patients converted to positive on several occasions; three times for UUPN 337 (once in 1996 and twice in 1997) and twice for UUPN 369, with subsequent clearing of their RSV colonization after therapy with ribavirin. All patients except UUPN 337 cleared the RSV with the 5 day regimen. UUPN 337 required two rounds of ribavirin ×5 days each time to clear the RSV positive events occurring on days +1 and +39. All patients other then UUPN 337 tested negative on the 48 and 72 h follow-up testing. The two patients that became positive a second or a third time had three to four negative NP washes done on a weekly basis between positive events. Nine of the 10 positive tests occurring in both 1996 and 1997 were in patients who were within 100 days of transplant. Six positive tests were in patients pre-engraftment. Two of the six positives pre-engraftment were in patients at the start of their transplant preparative regimen. Three positive tests were in patients post-engraftment, but before day +100. UUPN 337 had one of his three positive episodes at day +193.
All patients who turned RSV positive were asymptomatic at the time of their positive RSV status. One patient (UUPN 337) who converted three times received a family cord blood transplant for treatment of Wiskott-Aldrich disease. He was known to be RSV positive for several months prior to coming to transplant, but had been treated with ribavirin and RSVIG pre-transplant, entered transplant with no clinical symptoms, and was RSV negative by DFA. He was maintained on bi-weekly RSVIG throughout his transplant. At the time of his conversion to a positive RSV test he failed to demonstrate an increase in clinical symptoms and remained asymptomatic throughout his transplant. A second patient (UUPN 369), received an HLA-matched sibling transplant for treatment of myelodysplasia. She converted to a RSV-positive status twice but never showed evidence of clinical symptoms. None of the patients transplanted during the study ever developed clinical symptoms of RSV.
Discussion
RSV causes significant morbidity and mortality in some immunocompromised patients. Because of the high progression rate from upper tract disease to lower tract involvement in bone marrow transplant patients, with a subsequent high mortality rate, we studied the use of a preemptive approach to preventing the development of upper tract disease. This included routine screening during the RSV season of all patients prior to admission, and weekly during admission. In asymptomatic patients identified as RSV-positive, treatment with aerosolized ribavirin for 5 days cleared all but one patient of RSV. The patient who failed to clear with the first course of ribavirin cleared with a second 5-day course. The rate of positive RSV tests was 8% over both years. No transplant patients developed symptoms of upper or lower tract disease during our trial period.
RSV activity has been monitored weekly at our institution since 1991. Yearly RSV activity starts in October and usually lasts until April-May, with a peak during the month of February. For infection control purposes, the beginning of the RSV season was set once the laboratory identified two positive RSV tests in 1 week. The end of the season was determined once there were no new positive tests in the laboratory in a given week. This definition was observed during the 1996 and 1997 seasons. The majority of RSV-related hospitalizations occurred during the timeframe described above. The RSV seasons represented by the study were average RSV seasons at our institution. There were 372 and 439 hospital admissions to the general pediatric ward for RSV or bronchiolitis during the 1996 and 1997 RSV seasons encompassed by the study. Comparatively, there were 362 general pediatric admissions for RSV or bronchiolitis during the 1994-1995 season.
The incidence of asymptomatic, RSV-positive individuals is unknown, both in the patient who is immunologically compromised, and in the general population. Ljungman et al 13 prospectively evaluated 78 patients at the time of their admission for transplant, then again at set intervals during transplant, and with occurrence of symptoms. He demonstrated a 15% positive culture rate for respiratory viruses in patients during marrow transplantation. However, only one of the patients with positive culture was also asymptomatic. In addition, only one of the positive cultures was for RSV.
Several centers have reported variable success with ribavirin therapy, with or without the addition of RSVIG in the treatment of symptomatic, RSV-positive IC patients. Recently, McColl et al 8 have demonstrated the effectiveness of instituting ribavirin therapy in IC patients within 24 h of recognition of symptomatic RSV infection, both upper and lower tract disease. Eight patients developed symptoms of RSV. All patients were screened for RSV as soon as symptoms developed, and therapy with aerosolized ribavirin was initiated within 24 h of diagnosis. Five of the eight symptomatic patients were marrow transplant recipients. Three patients developed upper respiratory tract disease and two developed lower tract disease. All transplant patients responded appropriately to therapy, although two, one with upper tract disease, and one with lower tract disease, required two cycles of therapy to completely clear the RSV.
Whimbey et al 1 reported 12 patients with symptomatic upper tract RSV disease, who were treated with a combination of ribavirin and RSVIG. Ten of the 12 patients had disease confined to the upper tract, and all 10 survived. Two of the 12 patients developed lower tract disease, and both died of respiratory failure.
In a phase I/II study from the Fred Hutchinson Cancer Research Center reported by Bowden et al, 2 25 symptomatic patients testing positive for RSV were treated with aerosolized ribavirin 2 h per day for 7 days. All patients had symptoms confined to the upper tract at the start of therapy. Eight of 25 patients (32%) had progression of their symptoms to pneumonia, and the mortality rate in these eight patients was 29%.
Our results indicate that asymptomatic RSV infection may occur more frequently then previously recognized, especially in the IC pediatric population and that ribavirin is effective at clearing asymptomatic infections. The apparent success of this approach in avoiding the development of upper and lower respiratory tract disease has been encouraging. However, it is not clear that such preventative treatment of asymptomatic patients with ribavirin is necessary to prevent clinically significant disease. Ribavirin treatment is expensive, of unproven efficacy in BMT patients, and not without potential morbidity. We have therefore designed a randomized trial whereby all patients will be closely monitored, with asymptomatic, RSV-positive patients randomized to either ribavirin or close observation. Any RSVpositive patient who becomes symptomatic will be treated with ribavirin and RSVIG. This will determine the ability of pre-emptive therapy to avoid upper and lower respiratory tract disease.
